Welcome to our dedicated page for Petvivo Holdings news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on Petvivo Holdings stock.
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc. (OTCQB: PETVW) is a pioneering biomedical device company specializing in the development, manufacturing, and commercialization of innovative medical devices and therapeutics for companion animals and equines. The company’s unique approach involves adapting advanced human medical technologies for veterinary applications, enabling faster and more cost-effective solutions for pet healthcare needs. This strategy leverages investments in human biomaterials and medical device industries to address significant gaps in the veterinary market.
Core Business Model
PetVivo’s business model centers on licensing and in-house development of proprietary technologies designed specifically for veterinary use. By focusing on veterinary medical devices, the company benefits from shorter regulatory timelines compared to human pharmaceuticals and biologics, allowing for accelerated commercialization. PetVivo has built a robust intellectual property portfolio, with 21 patents covering biomaterials, products, production processes, and methods of use, underscoring its commitment to innovation and market differentiation.
Flagship Product: Spryng™ with OsteoCushion™ Technology
At the heart of PetVivo’s product offerings is Spryng™ with OsteoCushion™ Technology, a veterinarian-administered, intra-articular injectable medical device. Designed to address joint-related conditions such as osteoarthritis, lameness, and joint instability, Spryng is composed of sterilized extracellular matrix microparticles. These microparticles integrate with the synovial lining and subsynovial tissue to restore proper joint mechanics, offering a groundbreaking solution for managing noninfectious joint pain in cats, dogs, and horses. Clinical studies have demonstrated its efficacy in improving mobility and quality of life for affected animals.
Market Position and Industry Context
PetVivo operates within the rapidly growing veterinary healthcare market, driven by increasing pet ownership and rising expenditures on pet health. The company’s focus on joint health and its innovative approach to repurposing human medical technologies position it uniquely in this competitive landscape. By addressing a critical need for effective, minimally invasive solutions for joint-related conditions, PetVivo differentiates itself from traditional veterinary pharmaceutical and biologics companies.
Competitive Advantages
- Accelerated Time-to-Market: Veterinary medical devices face less stringent regulatory requirements compared to human pharmaceuticals, enabling faster commercialization.
- Proprietary Technology: A strong patent portfolio protects PetVivo’s innovations, ensuring a competitive edge in the market.
- Focus on Joint Health: The company’s specialization in addressing joint-related conditions fills a significant gap in veterinary therapeutics.
Challenges and Opportunities
While PetVivo’s strategy offers numerous advantages, the company faces challenges such as navigating regulatory frameworks for veterinary devices, building brand recognition among veterinarians, and competing with established players in the animal health industry. However, its focus on innovative, minimally invasive solutions and its ability to repurpose human medical technologies provide significant growth opportunities.
Conclusion
PetVivo Holdings, Inc. represents a compelling player in the veterinary healthcare market, combining innovation, intellectual property strength, and a strategic focus on addressing unmet needs in pet therapeutics. With its flagship product, Spryng™ with OsteoCushion™ Technology, the company is well-positioned to make a meaningful impact on the lives of companion animals and equines, while carving out a niche in the competitive landscape of veterinary medical devices.
PetVivo Holdings (OTCQB: PETV) has formed a strategic alliance with Digital Landia Corp. to integrate pet healthcare with AI technology. The partnership involves PetVivo exchanging $150,000 in restricted common stock for a 2% equity stake in Digital Landia and receiving 3 million Digital Landia tokens.
The collaboration centers on Pet AI, a platform that analyzes animal behavior with 97% accuracy through vocalizations, body language, and physiological signals. PetVivo's products, including SPRYNG® with OsteoCushion® Technology and Precise PRP®, will be exclusively promoted when the AI detects joint-related afflictions in pets.
The platform offers a freemium model with basic translation features and a $9.99/month subscription tier. The partnership targets a significant market, including 900 million dogs worldwide (25% with arthritis), 370 million cats, and 60 million horses, positioning PetVivo's joint treatment solutions within an AI-driven pet care ecosystem.
PetVivo Holdings (OTCQB: PETV) announced its participation in the Western Veterinary Conference (WVC) from March 2-5, 2025, at the Mandalay Bay Convention Center in Las Vegas. The company will showcase two key products: SPRYNG® with OsteoCushion® Technology, an intra-articular injectable veterinary device using sterilized, extra-cellular matrix microparticles for joint pain management, and PrecisePRP®, a novel off-the-shelf platelet-rich plasma product.
PrecisePRP® is notable for being leucoreduced, allogeneic, and requiring no blood draw or centrifugation, offering consistent dosing of 4 billion platelets per vial. The WVC, hosting over 15,000 participants, provides PetVivo an important platform to demonstrate these innovative solutions for osteoarthritis management in equine and companion animals.
PetVivo Holdings (OTCQB: PETV) reported fiscal Q3 2025 results with revenues of $583,000, up 191% sequentially but down 2% year-over-year. Distributor network sales reached $545,000, up 222% sequentially. The company maintained a strong gross margin of 89.5%, while operating loss improved by $375,000 to $1.8 million.
The company's lead product, Spryng with OsteoCushion Technology, is now used in over 800 veterinary clinics across all 50 states. PetVivo is shifting focus to include the larger companion animal market alongside its equine business, leading to sales force realignment. The company projects fiscal 2025 revenue of approximately $1.1 million, representing 10% growth.
Cash position stood at $29,000 as of December 31, 2024, but improved to $418,000 following a recent $1.1 million capital raise. Net cash used in operating activities decreased 31% compared to the previous year, reflecting improved operational efficiency.
PetVivo Holdings (OTCQB: PETV) has secured an Exclusive License and Supply Agreement with VetStem to commercialize PrecisePRP®, an innovative off-the-shelf platelet-rich plasma product for dogs and horses. This first-in-class product eliminates the need for blood draws or centrifugation, providing veterinarians with a consistent dose of 4 billion platelets per vial at 500,000 platelets per microliter.
The product undergoes rigorous safety screening according to FDA CVM Guidance 254, including infectious disease screening and blood type testing. Two randomized placebo-controlled safety studies revealed no treatment-related adverse events. PrecisePRP® will complement PetVivo's existing Spryng™ with OsteoCushion™ technology, reinforcing the company's position in veterinary medical devices and regenerative medicine.
PetVivo Holdings (OTCQB: PETV), a biomedical device company focused on commercializing innovative medical therapeutics for animals, has scheduled its Q3 FY2024 earnings release for Friday, February 14, 2025, after market close. The company will host a conference call and webcast to discuss the results at 2:00 p.m. CT (3:00 p.m. ET) on the same day.
Investors can access the live webcast through PetVivo's Investor Relations website, and a replay will be available following the conference call. The company has also provided dial-in details for those who prefer to join via phone.
PetVivo Holdings (OTCQB: PETV) has appointed Mike Eldred as Commercialization and Operations Advisor and Executive Director. Eldred brings 30 years of executive experience in animal health, notably serving as President of Dechra Pharmaceutical's North American Operations for 20 years, where he grew the subsidiary to over 250 employees and $400M+ in revenue.
The appointment aims to accelerate the adoption of Spryng™, PetVivo's intra-articular injectable veterinary medical device. Spryng uses OsteoCushion Technology, comprising sterilized extra-cellular matrix microparticles that integrate with animal subsynovial tissue to promote proper joint mechanics. Clinical studies have shown Spryng's effectiveness in treating lameness and joint-related conditions.
Prior to joining PetVivo, Eldred held senior positions at Virbac , Fort Dodge Animal Health, and Sanofi Animal Health, where he demonstrated success in business development, sales, and operations.
PetVivo Holdings (OTCQB: PETV) announced its participation in the Veterinary Meeting & Expo Conference from January 25-29, 2025, in Orlando, Florida. The company will showcase its flagship product, Spryng with OsteoCushion Technology, at booth #1825.
Spryng is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The product works by adsorbing onto animals' joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics. It's designed to manage noninfectious joint pain, including joint instability, degenerative joint disease, and osteoarthritis.
VMX, the largest veterinary conference in the United States, will provide PetVivo an opportunity to demonstrate Spryng's benefits to leading veterinarian surgeons and showcase its effectiveness in treating horses and companion animals across the U.S.
PetVivo Holdings (OTCQB: PETV) has announced new distribution partnerships with Vedco Inc. and Clipper Distributing, , both major players in veterinary product distribution. These partnerships will expand the distribution network for PetVivo's flagship product, Spryng™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device designed to manage joint pain in animals.
The partnerships connect PetVivo to major national veterinary product distributors including MWI, Covetrus, Patterson, Midwest Supply, and Penn Supply. Spryng is designed to promote joint pain management by augmenting and reinforcing cartilage to support normal joint function in cases where there is loss of cartilage or tissue-bone mechanical malfunction.
PetVivo Holdings (OTCQB: PETV and PETVW), a biomedical device company specializing in innovative medical therapeutics for animals, has announced a live webcast Shareholders Update Meeting scheduled for January 8, 2025 at 3:30 p.m. CT (4:30 p.m. ET).
The meeting will provide an overview of the company's progress in the 2025 fiscal year and discuss future prospects. Shareholders can access the webcast through PetVivo's Investor Relations website, and a replay will be available afterward. Additionally, participants can join via phone using the provided dial-in information.
PetVivo Holdings (OTCQB:PETV) has announced its participation in The Microcap Conference 2025, scheduled for January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. CEO John Lai will present a company overview and discuss their lead product, SPRYNG™ with OsteoCushion™ Technology.
SPRYNG is an intra-articular injectable veterinary medical device using sterilized, extra-cellular matrix microparticles. The product works by adsorbing onto animals' joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics and manage conditions like joint instability, degenerative joint disease, and osteoarthritis.
FAQ
What is the current stock price of Petvivo Holdings (PETVW)?
What does PetVivo Holdings, Inc. specialize in?
What is Spryng™ with OsteoCushion™ Technology?
How does PetVivo differentiate itself in the veterinary market?
What is PetVivo’s primary market focus?
What are the competitive advantages of PetVivo Holdings?
What types of animals benefit from PetVivo’s products?
What is the significance of PetVivo’s intellectual property portfolio?
How does PetVivo’s business model accelerate commercialization?
